Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting treatments on driving risks. It will reinforce the links between different research environments (sleep physiopathology, clinical research, cognitive neurosciences, drivers supervision, virtual reality, pharmacology) among the "Réseau Eveil Sommeil Attention et Transports" (RESAT) network.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Caen
• Treatments: Lactulose

Criteria

Inclusion Criteria:

• Cirrhosis proved by histologic or clinico-biologics criteria, whatever its severity, its stability defined by a child stable score (variation < 2 points for the last month) without any other disease which could be responsible of excessive daytime sleepiness

• driver's licence since at least 2 years

• driving more than 2000 Km/year

• registered to French national health and pensions organization

• having given their written light agreement in order to participate in the study.

Exclusion Criteria:

• Night workers

• neurologic disease

• recent strong complication (< 30 days)

• recent antibiotics or lactulose intake

• substance abusers (alcohol)

• hepatoma more than 5 cm

• disorder associated which engaged life prognostic in a short time

• glycemia fasted > 8 mmol/l

• haemoglobin < 10g/l

• neurologic or psychiatric disorders associated which affect superiors functions,

• hepatic encephalopathy stage 3 or 4

• having participated in a clinical study during the last 6 months

• drugs abusers

• unable to drive.